| Status: Recommended | ||
Insulin degludec (Tresiba®) is recommended as an option for use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year. |
||
|
||
Medicine details |
||
| Medicine name | insulin degludec (Tresiba®) | |
| Formulation | 100 units/ml and 200 units/ml solution for injection | |
| Reference number | 5196 | |
| Indication | Treatment of diabetes mellitus in adults, adolescents and children from the age of 1 year |
|
| Company | Novo Nordisk Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 1822 | |
| AWMSG meeting date | 14/09/2022 | |
| Date of issue | 03/10/2022 | |
| Further information This advice incorporates and replaces the AWMSG recommendation for insulin degludec (Tresiba®) for the treatment of diabetes mellitus in adult patients where treatment with a basal insulin analogue is considered appropriate (advice number 2816, originally published October 2016). |
||